Literature DB >> 27159758

Quality of Life and Sexual Function 2 Years After Vaginal Surgery for Prolapse.

Emily S Lukacz1, Lauren Klein Warren, Holly E Richter, Linda Brubaker, Matthew D Barber, Peggy Norton, Alison C Weidner, John N Nguyen, Marie G Gantz.   

Abstract

OBJECTIVE: To longitudinally assess the effect of native tissue vaginal apical prolapse repair with anti-incontinence surgery on quality of life, sexual function, and body image between uterosacral and sacrospinous suspensions.
METHODS: A planned secondary analysis was performed on 374 women enrolled in a randomized trial of the two types of native tissue repair for apical prolapse. Condition-specific and generic quality of life, sexual function, overall and de novo dyspareunia, and body image were assessed using validated instruments at baseline; 6, 12, and 24 months postoperatively; and changes from baseline were assessed and compared between surgical groups. General linear mixed models were used for comparisons and clinically significant differences were assessed using minimum important differences.
RESULTS: Of the women randomized, 82% had outcomes available at 2 years. Overall, clinically and statistically significant improvements in generic and condition-specific quality of life and sexual function were observed after surgery. Dyspareunia rates decreased from 25% to 16% by 24 months with only 3% of all women undergoing treatment. De novo dyspareunia occurred in 5% and 10% by 12 and 24 months, respectively. Body image scores also significantly improved from baseline. There were no clinically meaningful or statistically significant differences between groups for any of these outcomes (all P>.05).
CONCLUSION: Native tissue vaginal prolapse surgery results in statistically and clinically significant improvements in quality of life, sexual function, and body image at 24 months with no significant differences between uterosacral and sacrospinous suspensions. One in 10 women experience de novo dyspareunia but few requested treatment. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, www.clinicaltrials.gov, NCT00597935.

Entities:  

Mesh:

Year:  2016        PMID: 27159758      PMCID: PMC4879084          DOI: 10.1097/AOG.0000000000001442

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  14 in total

1.  Patient-reported outcome measures which assess body image in urogynaecology patients: a systematic review.

Authors:  Thomas G Gray; Rosanna Sneyd; Kaia Scurr; Georgina L Jones; David Iles; Swati Jha; Stephen C Radley
Journal:  Int Urogynecol J       Date:  2019-03-29       Impact factor: 2.894

2.  Modified laparoscopic pectopexy: short-term follow-up and its effects on sexual function and quality of life.

Authors:  Ali Emre Tahaoglu; Mehmet Sait Bakir; Nurullah Peker; İhsan Bagli; Ahter Tanay Tayyar
Journal:  Int Urogynecol J       Date:  2018-03-02       Impact factor: 2.894

3.  An international Urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for the assessment of sexual health of women with pelvic floor dysfunction.

Authors:  Rebecca G Rogers; Rachel N Pauls; Ranee Thakar; Melanie Morin; Annette Kuhn; Eckhard Petri; Brigitte Fatton; Kristene Whitmore; Sheryl A Kingsberg; Joseph Lee
Journal:  Int Urogynecol J       Date:  2018-03-26       Impact factor: 2.894

4.  Recruitment and retention: A randomized controlled trial of video-enhanced versus standard consent processes within the E-OPTIMAL study.

Authors:  Linda Brubaker; J Eric Jelovsek; Emily S Lukacz; Sunil Balgobin; Alicia Ballard; Alison C Weidner; Marie G Gantz; Ryan Whitworth; Donna Mazloomdoost
Journal:  Clin Trials       Date:  2019-07-26       Impact factor: 2.486

5.  Effect of Uterosacral Ligament Suspension vs Sacrospinous Ligament Fixation With or Without Perioperative Behavioral Therapy for Pelvic Organ Vaginal Prolapse on Surgical Outcomes and Prolapse Symptoms at 5 Years in the OPTIMAL Randomized Clinical Trial.

Authors:  J Eric Jelovsek; Matthew D Barber; Linda Brubaker; Peggy Norton; Marie Gantz; Holly E Richter; Alison Weidner; Shawn Menefee; Joseph Schaffer; Norma Pugh; Susan Meikle
Journal:  JAMA       Date:  2018-04-17       Impact factor: 56.272

6.  International Urogynecology Consultation Chapter 1 Committee 5: relationship of pelvic organ prolapse to associated pelvic floor dysfunction symptoms: lower urinary tract, bowel, sexual dysfunction and abdominopelvic pain.

Authors:  Marie-Andrée Harvey; Hui Ju Chih; Roxana Geoffrion; Baharak Amir; Alka Bhide; Pawel Miotla; Peter F W M Rosier; Ifeoma Offiah; Manidip Pal; Alexandriah Nicole Alas
Journal:  Int Urogynecol J       Date:  2021-08-02       Impact factor: 2.894

Review 7.  Pelvic organ prolapse and sexual function.

Authors:  Brigitte Fatton; Renaud de Tayrac; Vincent Letouzey; Stéphanie Huberlant
Journal:  Nat Rev Urol       Date:  2020-06-17       Impact factor: 14.432

8.  Generic Health-Related Quality of Life in Patients Seeking Care for Pelvic Organ Prolapse.

Authors:  Catherine S Bradley; Heidi W Brown; Stuart S Shippey; Robert E Gutman; Uduak U Andy; Ladin A Yurteri-Kaplan; Bela Kudish; Allen Mehr; Amy O'Boyle; Raymond T Foster; Jennifer T Anger; Patrick Ten Eyck; Pamela A Moalli
Journal:  Female Pelvic Med Reconstr Surg       Date:  2021-06-01       Impact factor: 1.913

9.  Perioperative Behavioral Therapy and Pelvic Muscle Strengthening Do Not Enhance Quality of Life After Pelvic Surgery: Secondary Report of a Randomized Controlled Trial.

Authors:  Alison C Weidner; Matthew D Barber; Alayne Markland; David D Rahn; Yvonne Hsu; Elizabeth R Mueller; Sharon Jakus-Waldman; Keisha Y Dyer; Lauren Klein Warren; Marie G Gantz; Susie Meikle
Journal:  Phys Ther       Date:  2017-11-01

10.  Impact of surgery on quality of life of Ugandan women with symptomatic pelvic organ prolapse: a prospective cohort study.

Authors:  Musa Kayondo; Dan Kabonge Kaye; Richard Migisha; Rodgers Tugume; Paul Kalyebara Kato; Henry Mark Lugobe; Verena Geissbüehler
Journal:  BMC Womens Health       Date:  2021-06-25       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.